Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 4/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31585319 | 0.83 | POLB (0.61) | POLBHCAR2KDM4EHTTALOX15 | |
| SCHEMBL27623883 | 0.83 | POLB (0.56) | POLBHCAR2KDM4EHTTALOX15 | |
| SCHEMBL16891501 | 0.81 | POLB (0.58) | POLBHCAR2KDM4EHTTALOX15 | |
| SCHEMBL15624546 | 0.81 | POLB (0.46) | POLBHCAR2KDM4EHTTALOX15 | |
| SCHEMBL30547547 | 0.79 | POLB (0.56) | POLBHCAR2KDM4EHTTALOX15 | |
| SCHEMBL25816382 | 0.79 | POLB (0.56) | POLBHCAR2KDM4EHTTALOX15 | |
| SCHEMBL5094634 | 0.78 | KDM4E (0.67) | POLBHCAR2KDM4EHTTALOX15 | |
| SCHEMBL7533255 | 0.78 | POLB (0.55) | POLBHCAR2KDM4EHTTALOX15 | |
| SCHEMBL1051595 | 0.78 | POLB (0.55) | POLBHCAR2KDM4EHTTALOX15 | |
| SCHEMBL6118965 | 0.77 | POLB (0.62) | POLBHCAR2KDM4EHTTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2537846-B1 | Intermediate compounds for preparing SMAC peptidomimetics | NOVARTIS AG (CH) | 2015-09-16 | — | — | EP | disclosed |
| EP-2102229-B1 | PYRROLYDINE DERIVATIVES AS IAP INHIBITORS | NOVARTIS AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| EP-2102229-B1 | PYRROLYDINE DERIVATIVES AS IAP INHIBITORS | NOVARTIS AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| US-20140004101-A1 | SMAC PEPTIDOMETICS USEFUL AS IAP INHIBITORS | NOVARTIS AG (CH) | 2014-01-02 | — | — | US | disclosed |
| US-8552003-B2 | (S)-N-((S)-1-cyclohexyl-2-{(S)-2-[4-4-(4-fluorobenzoyl)-thiazol-2-yl]pyrrolidin-1-yl}-2-oxoethyl)-2-methylamino-propionamide, or pharmaceutically acceptable salts thereof and their uses | NOVARTIS AG (CH) | 2013-10-08 | — | — | US | disclosed |
| US-8552003-B2 | (S)-N-((S)-1-cyclohexyl-2-{(S)-2-[4-4-(4-fluorobenzoyl)-thiazol-2-yl]pyrrolidin-1-yl}-2-oxoethyl)-2-methylamino-propionamide, or pharmaceutically acceptable salts thereof and their uses | NOVARTIS AG (CH) | 2013-10-08 | — | — | US | disclosed |
| US-8552003-B2 | (S)-N-((S)-1-cyclohexyl-2-{(S)-2-[4-4-(4-fluorobenzoyl)-thiazol-2-yl]pyrrolidin-1-yl}-2-oxoethyl)-2-methylamino-propionamide, or pharmaceutically acceptable salts thereof and their uses | NOVARTIS AG (CH) | 2013-10-08 | — | — | US | disclosed |
| US-8546336-B2 | SMAC peptidometics useful as IAP inhibitors | NOVARTIS AG (CH) | 2013-10-01 | — | — | US | disclosed |
| US-8546336-B2 | SMAC peptidometics useful as IAP inhibitors | NOVARTIS AG (CH) | 2013-10-01 | — | — | US | disclosed |
| US-8546336-B2 | SMAC peptidometics useful as IAP inhibitors | NOVARTIS AG (CH) | 2013-10-01 | — | — | US | disclosed |
| US-20110015232-A1 | Pyrrolydine Derivatives as IAP Inhibitors | NOVARTIS AG | 2011-01-20 | — | — | US | disclosed |
| US-20110015232-A1 | Pyrrolydine Derivatives as IAP Inhibitors | NOVARTIS AG | 2011-01-20 | — | — | US | disclosed |
| US-20110015232-A1 | Pyrrolydine Derivatives as IAP Inhibitors | NOVARTIS AG | 2011-01-20 | — | — | US | disclosed |
| CN-101595121-A | Pyrrolidine derivatives as IAP inhibitors | NOVARTIS AG (CH) | 2009-12-02 | — | — | CN | disclosed |
| EP-2102229-A1 | PYRROLYDINE DERIVATIVES AS IAP INHIBITORS | Novartis AG (CH) | 2009-09-23 | — | — | EP | disclosed |
| CN-101511860-A | SMAC peptidomimetics useful as IAP inhibitors | NOVARTIS AG (CH) | 2009-08-19 | — | — | CN | disclosed |
| EP-2051990-A1 | SMAC PEPTIDOMIMETICS USEFUL AS IAP INHIBITORS | Novartis AG (CH) | 2009-04-29 | — | — | EP | disclosed |
| WO-2008045905-A1 | PYRROLYDINE DERIVATIVES AS IAP INHIBITORS | NOVARTIS AG (CH) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008045905-A1 | PYRROLYDINE DERIVATIVES AS IAP INHIBITORS | NOVARTIS AG (CH) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008016893-A1 | SMAC PEPTIDOMIMETICS USEFUL AS IAP INHIBITORS | NOVARTIS AG (CH) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140004101-A1 | SMAC PEPTIDOMETICS USEFUL AS IAP INHIBITORS | BIRC5, BIRC2, BIRC7 | POLB 1495/4885HCAR2 4184/4885KDM4E 2517/4885 |
| US-20110015232-A1 | Pyrrolydine Derivatives as IAP Inhibitors | XIAP, BIRC5, BIRC3 | POLB 3154/4885HCAR2 1985/4885KDM4E 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.